Citadel Advisors’s Mustang Bio MBIO Stock Holding History

Citadel Advisors’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Hold	0	–	-$37	–	14875
2023 Q1	–	Hold	0	–	–	–	14613
2022 Q4	–	Hold	0	–	–	–	14792
2022 Q2	–	Sell	-14	Closed	-$10K	–	13610
2022 Q1	$10K	Sell	14 -20	-59%	-$16.4K	﹤0.01%	13379
2021 Q4	$42K	Sell	34 -63	-65%	-$102K	﹤0.01%	13339
2021 Q3	$196K	Buy	97 +14	+17%	+$30.1K	﹤0.01%	12012
2021 Q2	$208K	Sell	83 -39	-32%	-$95.6K	﹤0.01%	12069
2021 Q1	$304K	Buy	122 +11	+10%	+$32.7K	﹤0.01%	10829
2020 Q4	$316K	Buy	111 +4	+4%	+$9.56K	﹤0.01%	8983
2020 Q3	$252K	Buy	107 +57	+114%	+$140K	﹤0.01%	8427
2020 Q2	$119K	Buy	50 +28	+127%	+$65.5K	﹤0.01%	8892
2020 Q1	$45K	Buy	22 +8	+57%	+$20.5K	﹤0.01%	9077
2019 Q4	$44K	Buy	+14	New	+$32.1K	﹤0.01%	8788

Other funds holding MBIO

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Citadel Advisors's MBIO Position: Q1 2026 in Review

Citadel Advisors reduced its Mustang Bio (MBIO) stake by 37% in Q1 2026, selling an estimated $29.7K and leaving 53,200 shares worth $38.7K. The position accounts for ﹤0.01% of the portfolio, ranked #12498.

Citadel Advisors first reported a position in MBIO in Q3 2018 and has held it in 20 quarters since. The position peaked at $679K in Q3 2020. 22 funds tracked by Wall St. Rank hold MBIO as of Q1 2026.

Citadel Advisors held 53,200 shares of Mustang Bio worth $38.7K as of Q1 2026.
Citadel Advisors sold 31,565 Mustang Bio shares in Q1 2026, an estimated $29.7K.
Mustang Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12498 holding.
Citadel Advisors first reported a position in Mustang Bio in Q3 2018 and has held it in 20 quarters since.
Citadel Advisors's Mustang Bio position peaked at $679K in Q3 2020.
22 funds tracked by Wall St. Rank held Mustang Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.